Interferon ␥ (IFN␥) acts on human erythroid colony-forming cells (ECFCs) to up-regulate Fas, without a demonstrable change of Fas ligand (FasL) or Fasassociated DD-containing protein (FADD) expression and activates caspase-8 plus caspase-3, which produce apoptosis. Our previous data showed that stem cell factor (SCF) reduced the inhibitory effect of IFN␥ on human ECFCs when both factors were present in the cultures. However, the mechanism by which SCF prevents IFN␥-induced apoptosis in ECFCs is unclear. In this study we used highly purified human ECFCs to investigate the mechanism of the effect of SCF on IFN␥-induced apoptosis. 
Introduction
Fas (CD95/APO-1) is a prominent member of the death receptor family. Its cardinal death-signaling function is ensured by the presence of a cytoplasmic protein-protein interaction motif called the death domain (DD). 1 Clustering of Fas induces association of the cytoplasmic adaptor protein Fas-associated DD-containing protein (FADD) with the oligomerized DD of the receptor. 2, 3 FADD in turn recruits the zymogen form of the initiator caspase-8/FADDlike interleukin 1 ␤ (IL-1␤)-converting enzyme (FLICE), [4] [5] [6] thus leading to the formation of the death-inducing signaling complex (DISC) that is the most receptor-proximal element of signal transduction by Fas. 7 Recruitment of the zymogen form of caspase-8 to the DISC leads to its autoproteolytic cleavage and the release of its active enzyme form in the cytosol, which initiates the cascade of caspase activation and apoptosis. One mechanism for inhibition of Fas-mediated apoptosis occurs through the action of FLICE-inhibitory protein (FLIP), a novel Fas pathway inhibitory protein, which acts as a dominant-negative caspase-8. 8, 9 The inhibitory effects of interferon ␥ (IFN␥) on murine and human granulocyte-macrophage colony-forming units (CFUGMs), burst-forming units-erythroid (BFU-Es), and colonyforming units-erythroid (CFU-Es) in vitro have been reported by many investigators. [10] [11] [12] [13] [14] [15] [16] [17] Experiments in our laboratory have shown that IFN␥ reduced erythroid colony formation, cell proliferation, and differentiation of highly purified human day Ϫ3 to day Ϫ6 BFU-Es in a dose-dependent manner and produced profound erythroblast apoptosis. 17 We also have shown that IFN␥ markedly increased the percentage of cells expressing Fas on the surface of human erythroid colony-forming cells (ECFCs) as well as the intensity of Fas expression on these cells and induced the upregulation and activation of caspase-8 and caspase-3 to produce apoptosis in human ECFCs. 18, 19 Stem cell factor (SCF) has an essential role in the development of erythroid cells and affects intracellular signaling associated with proliferation, differentiation, and survival of erythroid progenitor cells. [20] [21] [22] [23] [24] Several studies have shown that SCF reduces IFN␥-induced inhibition of ECFC development 17 and Fas-mediated apoptosis in hematopoietic progenitor cells. Nishio et al 25 
Materials and methods

Generation of ECFCs
This method has been previously described. 27 In brief, 400 mL of blood was obtained from healthy donors who signed consent forms approved by the Vanderbilt Committee for the Protection of Human Subjects and the Nashville Department of Veterans Affairs Research and Development Committee. BFU-Es (day-0 cells) were purified by sequential density gradient centrifugation, depletion of platelets and lymphocytes, and removal of adherent cells after overnight culture. A further negative selection and removal of contaminant cells with CD2, CD11b, CD16, and CD45 monoclonal antibodies was performed as previously described. 18, 27 The day Ϫ1 BFU-Es were suspended in Iscove modified Dulbecco medium (IMDM) containing 20% heat-inactivated fetal calf serum (FCS), 5% heat-inactivated, pooled, human AB serum, 1% deionized bovine serum albumin (BSA), 5 ϫ 10 Ϫ5 M 2-mercaptoethanol, 10 g/mL insulin (Sigma, St Louis, MO), 2 U/mL erythropoietin (Amgen, Thousand Oaks, CA), 50 U/mL IL-3 (R&D Systems, Minneapolis, MN), 100 ng/mL SCF (Amgen), and streptomycin plus penicillin to generate ECFCs. After 5 days of culture the average purity of day Ϫ6 ECFCs was 60% or higher as measured by the plasma clot assay. The day-6 cells were then collected and further incubated in the above medium lacking IL-3, with or without SCF, IFN␥ 1ϫ 10 7 U/mg (R&D Systems), and FasL (R&D Systems) in liquid suspension. In some experiments, BFU-Es were incubated for additional days as indicated.
Western blot analysis
Whole cell lysates were prepared in lysis buffer (1% Triton X-100, 20 mM Tris (tris(hydroxymethyl)aminomethane)-HCl, pH 7.5, 140 mM NaCl, 100 mM sodium fluoride, 10 mM EDTA (ethylenediaminetetraacetic acid), 2 mM vanadate, 0.2 mM phenylmethylsulfonyl fluoride, and 0.15 U/mL aprotinin). Equivalent amounts of total cellular protein were electrophoresed on 10% or 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred to nitrocellulose membranes (BIO-RAD, Hercules, CA). The membranes were blocked in 5% dry milk in 0.05% Tween 20-Trisbuffered saline (TBST) for 2 hours at room temperature. Incubation with primary antibodies was done at 4°C overnight, and incubation with secondary horseradish peroxidase (HRP)-linked antibodies (Amersham Pharmacia Biotech, Piscataway, NJ) was performed for 1 hour at room temperature. After washing the membranes extensively in TBST, antibody binding was detected by using enhanced chemiluminescence (Amersham Pharmacia Biotech). Antibodies used in this study are as follows: polyclonal rabbit anti-FLIP antibody (kindly provided by Dr Donald Nicholson and Merck Frosst Canada, Quebec, Canada), polyclonal anticaspase-3 antibody (BD Pharmingen, San Diego, CA), monoclonal anticaspase-8 antibody (Cell Signaling Technology, Beverly, MA), and monoclonal antiactin antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
RNA preparation and Northern analysis
Total RNA was prepared from ECFCs treated with or without SCF for 48 and 96 hours using ULTRASPEC (BIOTECX Laboratories, Houston, TX). The full sequence of FLIP was used as DNA probe. Quantification of RNA, formaldehyde gel electrophoresis, blotting onto nylon membranes, and hybridization with 32 P-labeled FLIP probe were performed as previously described. 18 To verify sample loading variation, the same blots were reprobed with human G3PDH cDNA control probes that were purchased from Clontech (Palo Alto, CA).
Transfection with FLIP antisense oligonucleotides
We used FLIP antisense oligonucleotides (ASOs) and nonsense oligonucleotides (NSOs) as reported by Bannerman et al 28 with a little modification.
The 2Ј-O-methyl/2Ј-deoxynucleotide chimeric oligonucleotides 28, 29 used in all experiments were synthesized by Operon Technologies (Alameda, CA). Chimeric oligonucleotides were used to support an RNase H-dependent mechanism of action, which results in a selective loss of target mRNA. 30 The FLIP ASOs contained 8 mismatches, as compared with the control NSOs. The sequence of the ASOs to FLIP is 5Ј-ACUUGTCCCTGCTCCUU-GAA-3Ј and the sequence of the NSOs is 5Ј-UCUAGCCTCTC-CTCGUAGUA-3Ј. The first 5 and last 5 bases represent 2Ј-O-methylmodified nucleotides. The middle 10 bases represent 2Ј-deoxynucleotides. Oligonucleotides are further modified with phosphorothioate linkages. Day Ϫ5 ECFCs were incubated with or without SCF (30 ng/mL) for 48 hours. FLIP ASOs or NSOs were added to day Ϫ7 ECFCs at 1 M final concentrations and were incubated in the presence of Oligofectamine (Gibco BRL, Gaithersburg, MD) in 5% serum medium for 12 hours. IFN␥ (400 U/mL) and FasL (50 ng/mL) were then added to the ECFCs for an additional 36 hours of incubation at 37°C. Down-regulation of the relative protein levels was evaluated by immunoblotting, and apoptosis was evaluated by terminal uridine dUTP nick-end labeling (TUNEL) assay at 48 hours after ASO and NSO incubation.
TUNEL assay for quantitation of apoptotic cells
Apoptotic cells were identified by the TUNEL method using an in situ cell death detection kit (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions. Briefly, ECFCs were harvested and washed twice in phosphate-buffered saline (PBS). After centrifugation, cell pellets were resuspended in 200 L PBS containing 4% paraformaldehyde for 1 hour at 26°C and were washed twice again. Permeabilization was conducted by using 100 L 0.1% Triton X-100 and 0.1% sodium citrate in PBS. After washing, the cells were resuspended in TUNEL reaction mixture containing fluorescein isothiocyanate (FITC)-dUTP and terminal-deoxynucleotidyl-transferase (TdT). Control cells were suspended in the TUNEL reaction mixture containing FITC-dUTP without TdT, and incubations were performed for 1 hour at 37°C before washing the cells twice. Fluorescein labels incorporated into DNA strand breaks were detected by flow cytometry.
Statistics
Student t test was used to determine statistical significance. The minimal level of significance was P ϭ .05.
Results
Addition of FasL augments caspase-8 and caspase-3 activation induced by IFN␥
IFN␥ increases the percentage of cells expressing Fas on the surface of the human ECFCs as well as the intensity of Fas expression and induces the activation of caspase-8 and caspase-3 in human ECFCs. 16, 17 We added the FasL with IFN␥ to augment caspase-8 and caspase-3 activation and apoptosis. Human day Ϫ6 ECFCs were treated with IFN␥ (400 U/mL) and/or FasL (10, 25, or 50 ng/mL) for 48 hours at 37°C, and cell lysates were prepared and probed with the anticaspase-8 and anticaspase-3 antibodies. The addition of FasL augments caspase-8 and caspase-3 activation induced by IFN␥ in a dose-dependent manner (data not shown). When day Ϫ6 ECFCs were cultured with medium with or without IFN␥ (400 U/mL) and FasL (50 ng/mL) for 24 to 96 hours, the cleavage of caspase-8 and caspase-3 was increased during 24 hours of incubation with IFN␥/FasL, and the activation of caspase-8 and caspase-3 persisted or further increased over 96 hours (Figure 1 ).
SCF inhibits caspase-8 and caspase-3 activation and apoptosis induced by IFN␥
To investigate the effect of SCF on IFN␥ and/or FasL-induced caspase-8 and caspase-3 activation and apoptosis, day Ϫ6 ECFCs were cultured in medium with or without IFN␥ (400 U/mL), FasL (50 ng/mL), or SCF (100 ng/mL). After 72 hours of incubation at 37°C, cell lysates were prepared, and immunoblot analysis was performed with anticaspase-8 and caspase-3 antibodies. As shown in Figure 2 , the addition of FasL (50 ng/mL) augmented the activation of caspase-8 and caspase-3 induced by IFN␥, and SCF clearly reduced the activation of caspase-8 and caspase-3 induced by IFN␥ and FasL. TUNEL assay showed that the percentage of apoptotic cells was 27% in the IFN␥-treated group and 50% in the IFN␥/FasL-treated group after 120 hours of incubation at 37°C in 5% serum medium (Figure 3 ). The addition of SCF decreased the percentage of apoptotic cells to 6% in the IFN␥-treated group and to 18% in the IFN␥/FasL-treated group. The same pattern was present in 6 experiments using slightly different time intervals. These experiments showed that SCF inhibits apoptosis induced by IFN␥ and/or FasL. Consistent with reported data, 25 SCF did not decrease the surface expression of Fas on the ECFCs (data not shown), which suggests that SCF acts on a pathway downstream of Fas and upstream of the caspase cascade to inhibit apoptosis.
SCF increases the expression of FLIP protein and mRNA
We evaluated the effect of SCF on FLIP expression because FLIP has been reported to interact with FADD and/or caspase-8 at the DISC level after Fas stimulation and to act as a dominant-negative caspase-8. To identify the potential involvement of FLIP in the SCF protection pathway, we incubated day Ϫ6 ECFCs for up to 72 hours with SCF (100 ng/mL) and incubated day Ϫ6 ECFCs with increasing concentrations of SCF for 48 hours. Because day Ϫ1 BFU-Es were incubated in medium containing SCF (100 ng/mL) and SCF is present in serum at a concentration of approximately 3 ng/mL, in our initial experiments the day Ϫ5 ECFCs were washed twice with PBS and then were incubated in low (5%) serum medium at 37°C for the duration of the experiment in an attempt to reduce baseline stimulation by SCF. As shown in Figure 4A , the increase of FLIP protein was detectable after 36 hours, reaching a maximum by 72 hours of incubation with SCF. An increase of FLIP protein was evident at an SCF concentration of 25 ng/mL and continued to increase at 50 to 100 ng/mL when day Ϫ6 ECFCs were incubated with SCF for 48 hours ( Figure 4B ). In subsequent experiments the prior incubation in 5% serum medium was omitted. We then incubated day Ϫ6 ECFCs in regular medium with or without SCF and assayed FLIP protein expression and FLIP mRNA levels. Immunoblot experiments showed that FLIP L expression level was much higher in the group treated with SCF (100 ng/mL) compared with the control group after 72 hours of incubation ( Figure 4C ). IFN␥ or FasL did not change FLIP expression. When we added SCF together with IFN␥ or IFN␥/ FasL, the FLIP expression level was higher than when IFN␥ or FasL was added alone but was less than when SCF was added alone. The FLIP mRNA expression level was also higher in the SCF-treated group than in the control group after 48 and 96 hours of incubation ( Figure 4D ). These findings suggest that the increase in the FLIP protein is most likely controlled by the level of mRNA and that SCF may be acting through transcriptional up-regulation. Day Ϫ6 ECFCs were incubated in medium with or without IFN␥ (400 U/mL), FasL (50 ng/mL), or SCF (100 ng/mL) at 37°C for 120 hours in 5% serum medium, and apoptosis was determined by TUNEL assay.
in both the SCF-treated and -untreated groups ( Figure 5A ). Reduction of FLIP expression with ASOs enhanced the IFN␥/FasLinduced apoptosis of the ECFCs. ECFCs treated with SCF and NSO had reduced apoptosis compared with cells treated with NSO without SCF, but this effect of SCF was not seen in ASO-treated cells, demonstrating a definitive role for FLIP in the protection of ECFCs from IFN␥ and FasL-induced apoptosis ( Figure 5B ). These experiments showed that antiapoptotic effect of SCF against IFN␥ and FasL in human ECFCs is due at least partly to the increased expression of FLIP by SCF.
Discussion
Other investigators have reported that SCF inhibits apoptosis of ECFCs induced by CH11, a Fas ligand-mimetic antibody, 25, 26 but the mechanism by which SCF mediates this process is not known. To investigate the mechanism by which SCF reduces IFN␥-induced apoptosis in ECFCs, we first examined the effect of SCF on the Jak/STAT1 (janus kinase signal transducer and activator of transcription 1) pathway activated by IFN␥. Biologic responses to IFN␥ are mediated mainly by the regulation of gene expression, and it has been established that most of the pleiotropic effects of IFN␥ are mediated by several gene products that are regulated by the Jak-STAT1 pathway. 31 Our experiments showed that IFN␥ definitively induced the phosphorylation of STAT1 and expression of IRF1 (IFN-regulatory factor 1) in the ECFCs, but SCF did not affect the phosphorylation of STAT1 and the expression of IRF1 induced by IFN␥ (I.-J.C., C.D., and S.B.K., unpublished data, 2001). Although the lack of an apparent SCF effect on STAT1 could be due to an activation of STAT1 by SCF that counterbalanced a change in the IFN␥ activation or could be due to activation of a STAT1-independent pathway, we decided to examine an effect on later events in the traditional IFN␥ transduction pathway.
We evaluated the effect of SCF on the Fas pathway and the caspase cascade because our previous data showed that IFN␥ markedly increased the percentage of cells expressing Fas on the surface of the human ECFCs as well as the intensity of Fas expression and induced the activation of caspase-8 and caspase-3 to produce apoptosis in human ECFCs. 18, 19 This was greatly reduced by both NOK-2 antihuman Fas ligand and soluble Fas ligand receptor, Fas-Fc. 18 As shown in Figures 2 and 3 , SCF inhibited the activation of caspase-8 and caspase-3 along with the apoptosis induced by IFN␥ and/or FasL. Consistent with reported data, 25 we also found that SCF did not decrease the surface expression of Fas on the ECFCs (unpublished data, 2001). These Cell lysates were prepared, and immunoblot analyses were performed with anti-FLIP antibody. (B) Apoptosis was determined by TUNEL assay, and the percentages of apoptotic cells were expressed as the mean Ϯ SD from 4 independent experiments. *P Ͻ .05, ASO-treated group versus NSO-treated group (without SCF preincubation); **P Ͻ .05, ASO-treated group versus NSO-treated group (with SCF preincubation); ***P Ͻ .05, NSO-treated group without SCF preincubation versus NSO-treated group with SCF preincubation; ****P ϭ .21, ASO-treated group without SCF preincubation versus ASO-treated group with SCF preincubation. ECFCs were cultured at 37°C in regular medium with or without IFN␥ (400 U/mL), FasL (50 ng/mL), or SCF (100 ng/mL) for 72 hours. FLIPL protein was determined by immunoblot analysis. (D) Without a prior incubation in 5% serum medium, day Ϫ6 ECFCs were cultured in regular medium with or without SCF (100 ng/mL) for 48 and 96 hours. FLIP mRNA was determined by Northern blot analysis.
observations suggested that SCF acts on the pathway downstream of Fas and upstream of the caspase cascade to inhibit apoptosis.
FLIP, which structurally resembles caspase-8, was identified as a cellular homologue of viral FLIPs, except that it lacks proteolytic activity. 8, 9, 32 FLIP is recruited to the Fas DISC through the adaptor molecule FADD similar to caspase-8, thereby preventing the recruitment of caspase-8 into the complex and subsequent caspase-8 activation. 33 Cellular FLIP (c-FLIP) is found mainly with 2 splice variants, a long form (FLIP L ) and a short form (FLIP S ). 33 So far, most of the studies concerning FLIP have focused on the long form, FLIP L , most likely because it is generally more abundant in cells. Both c-FLIP L and c-FLIP S block procaspase-8 activation at the DISC even though the 2 splice variants produce this effect in a distinctly different way. 34 The signaling pathways by which FLIP expression is modulated are not well understood. In the present study, we found that increased expression of FLIP is clearly induced by SCF in human ECFCs (Figure 4) . Reduction of FLIP expression with ASOsensitized ECFCs to IFN␥/FasL-induced apoptosis ( Figure 5 ), demonstrating a definitive role for FLIP in the protection of ECFCs from IFN␥/FasL-induced apoptosis. These experiments also showed that the antiapoptotic effect of SCF against IFN␥/FasL in human ECFCs was greatly reduced by the ASOs. The fact that SCF increases FLIP and reduces apoptosis, coupled with the fact that ASOs to FLIP prevent the increase in FLIP and at the same time prevent the decrease in apoptosis produced by SCF, lead us to the conclusion that SCF inhibits IFN␥/FasL-induced apoptosis through increased FLIP expression.
